New Zealand markets open in 9 hours 51 minutes

MaaT Pharma SA (MAAT.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
9.46+0.06 (+0.64%)
As of 10:40AM CEST. Market open.
Full screen
Previous close9.40
Open9.46
BidN/A x N/A
AskN/A x N/A
Day's range9.40 - 9.46
52-week range4.50 - 9.90
Volume279
Avg. volume1,601
Market cap109.761M
Beta (5Y monthly)0.25
PE ratio (TTM)N/A
EPS (TTM)-1.70
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est15.70
  • Business Wire

    MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024

    LYON, France, May 07, 2024--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today provided a business update and highlights its key milestones for 2024.

  • Business Wire

    MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

    LYON, France, May 06, 2024--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival of patients with cancer, today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des

  • Business Wire

    MaaT Pharma to Hold Annual General Meeting on May 28, 2024

    LYON, France, April 22, 2024--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, informs its shareholders that the Annual General Meeting (ordinary and extraordinary) will be held on May, 28, 2024, at 11:00 a.m. CET at the Company’s headquarter in France located at 70 avenue Tony Garnier, 69007 Lyon.